EP1556074A4 - Casein derived peptides and uses thereof in therapy - Google Patents

Casein derived peptides and uses thereof in therapy

Info

Publication number
EP1556074A4
EP1556074A4 EP02758768A EP02758768A EP1556074A4 EP 1556074 A4 EP1556074 A4 EP 1556074A4 EP 02758768 A EP02758768 A EP 02758768A EP 02758768 A EP02758768 A EP 02758768A EP 1556074 A4 EP1556074 A4 EP 1556074A4
Authority
EP
European Patent Office
Prior art keywords
therapy
derived peptides
casein derived
casein
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02758768A
Other languages
German (de)
French (fr)
Other versions
EP1556074A2 (en
Inventor
Zvi Sidelman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chay 13 Medical Res Group NV
Original Assignee
Chay 13 Medical Res Group NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/942,121 external-priority patent/US20020147144A1/en
Application filed by Chay 13 Medical Res Group NV filed Critical Chay 13 Medical Res Group NV
Publication of EP1556074A2 publication Critical patent/EP1556074A2/en
Publication of EP1556074A4 publication Critical patent/EP1556074A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4732—Casein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • AIDS & HIV (AREA)
  • Emergency Medicine (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
EP02758768A 2001-08-30 2002-08-29 Casein derived peptides and uses thereof in therapy Withdrawn EP1556074A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US942121 2001-08-30
US09/942,121 US20020147144A1 (en) 2000-03-01 2001-08-30 Casein derived peptides and uses thereof in therapy
PCT/IL2002/000720 WO2003018606A2 (en) 2001-08-30 2002-08-29 Casein derived peptides and uses thereof in therapy

Publications (2)

Publication Number Publication Date
EP1556074A2 EP1556074A2 (en) 2005-07-27
EP1556074A4 true EP1556074A4 (en) 2008-05-07

Family

ID=25477603

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02758768A Withdrawn EP1556074A4 (en) 2001-08-30 2002-08-29 Casein derived peptides and uses thereof in therapy

Country Status (15)

Country Link
EP (1) EP1556074A4 (en)
JP (1) JP2005511499A (en)
KR (1) KR20040078639A (en)
CN (1) CN1694719A (en)
AU (1) AU2002324323A2 (en)
BR (1) BR0212625A (en)
CA (1) CA2458924A1 (en)
CZ (1) CZ2004335A3 (en)
HU (1) HUP0500995A3 (en)
IL (1) IL160548A0 (en)
MX (1) MXPA04001890A (en)
NO (1) NO20040880L (en)
PL (1) PL375113A1 (en)
WO (1) WO2003018606A2 (en)
ZA (1) ZA200401574B (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0313892D0 (en) * 2003-06-16 2003-07-23 Hannah Res Inst Control of lactation
US20050192312A1 (en) * 2004-01-30 2005-09-01 Brown Dennis M. Naphthalimide dosing by N-acetyl transferase genotyping
US20070203060A1 (en) * 2004-03-01 2007-08-30 Zvi Sidelman Casein Derived Peptides And Therapeutic Uses Thereof
GB0423352D0 (en) 2004-10-21 2004-11-24 Hannah Res Inst "Control of mammary cell number"
ES2319475B1 (en) * 2005-06-08 2010-02-16 Consejo Superior Investig. Cientificas BIOACTIVE PEPTIDES IDENTIFIED IN ENZYMATIC HYDROLYZES OF LACTEE CASEINS AND PROCEDURE OF OBTAINING.
JP4394155B2 (en) 2006-06-09 2010-01-06 森永乳業株式会社 Lipid metabolism improver
JP2011026213A (en) * 2009-07-22 2011-02-10 Snow Brand Milk Prod Co Ltd Type 1 diabetes-inhibiting peptide
JP2015520129A (en) * 2012-04-16 2015-07-16 ザ クリーブランド クリニック ファウンデーション Multivalent breast cancer vaccine
AU2018227125A1 (en) * 2017-03-03 2019-10-24 Morinaga Milk Industry Co., Ltd. GLP-1 secretagogue and composition
CN107814835B (en) * 2017-12-01 2020-04-28 熊猫乳品集团股份有限公司 Bioactive polypeptide AVPITPTLNREQ, and preparation method and application thereof
CN108017709B (en) * 2017-12-12 2020-04-10 浙江辉肽生命健康科技有限公司 Bioactive polypeptide KEPMIGVNQELA, and preparation method and application thereof
CN113952446B (en) * 2021-09-03 2023-12-05 河南省医药科学研究院 Application of bioactive peptide in inhibiting bone marrow toxicity

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2118134A1 (en) * 1970-12-16 1972-07-28 Assad Najjar V
WO2001064234A1 (en) * 2000-03-01 2001-09-07 Chay 13 Medical Research Group N.V. Casein derived peptides and uses thereof in therapy

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0922769A4 (en) * 1997-03-21 2000-07-12 Snow Brand Milk Products Co Ltd Iron-casein complex hydrolyzate and process for the production thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2118134A1 (en) * 1970-12-16 1972-07-28 Assad Najjar V
WO2001064234A1 (en) * 2000-03-01 2001-09-07 Chay 13 Medical Research Group N.V. Casein derived peptides and uses thereof in therapy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KARIYA K ET AL: "INHIBITION OF ANGIOTENSIN CONVERTING ENZYME OF RAT BRAIN WITH BRADYKININ AND ITS FRAGMENTS", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS, SAN DIEGO, CA, US, vol. 100, no. 1, 1981, pages 31 - 36, XP008066034, ISSN: 0006-291X *

Also Published As

Publication number Publication date
AU2002324323A2 (en) 2003-03-10
WO2003018606A3 (en) 2005-05-06
NO20040880L (en) 2004-04-20
HUP0500995A3 (en) 2008-09-29
PL375113A1 (en) 2005-11-28
CN1694719A (en) 2005-11-09
WO2003018606A2 (en) 2003-03-06
KR20040078639A (en) 2004-09-10
JP2005511499A (en) 2005-04-28
IL160548A0 (en) 2004-07-25
BR0212625A (en) 2007-06-19
HUP0500995A2 (en) 2007-05-02
EP1556074A2 (en) 2005-07-27
CZ2004335A3 (en) 2004-07-14
ZA200401574B (en) 2007-02-28
CA2458924A1 (en) 2003-03-06
MXPA04001890A (en) 2004-06-18
WO2003018606A9 (en) 2004-04-08

Similar Documents

Publication Publication Date Title
HUP0301003A3 (en) Casein derived peptides and uses thereof in therapy
HUP0500992A3 (en) Tacis and br3 polypeptides and uses thereof
EP1461605A4 (en) Protein and peptide nanoarrays
HUP0500989A2 (en) Animicrobial polypeptides and their uses
AU2002365396A8 (en) Peptides, peptide compositions,and methods of use in binding p 185
EP1578769A4 (en) Peptides and the use thereof in darkening the skin
HUP0500995A2 (en) Casein derived peptides and uses thereof in therapy
EP1414848A4 (en) Replikin peptides and uses thereof
EP1419175A4 (en) Replikin peptides and uses thereof
SI1462455T1 (en) Ser-Ser-Ser-Arg peptide and medicinal uses thereof
IL131707A0 (en) Acetylcholinesterase-derived peptides and uses thereof
GB9918155D0 (en) Proteins and peptides
GB0026134D0 (en) Peptides and their use
EP1080185A4 (en) Myelin basic protein peptides and uses thereof
IL144225A0 (en) ((aminoiminomethyl) amino) alkanecarboxamides and their applications in therapy
IL151351A0 (en) Casein derived peptides and uses thereof in therapy
EP1395276A4 (en) Structurally modified peptides and uses thereof
GB0102447D0 (en) Protein variants and uses thereof
SG2012018057A (en) Replikin peptides and uses thereof
GB0108752D0 (en) Peptide epitopes and uses thereof
IL158109A0 (en) Replikin peptides and uses thereof
IL159495A0 (en) Replikin peptides and uses thereof
HK1044546A1 (en) Retro-inverso prosaposin-derived peptides and use thereof
GB0017028D0 (en) Peptides and their therapeutic use
AU4726901A (en) Novel human proteins and polynucleotides encoding the same

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040313

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20080403

17Q First examination report despatched

Effective date: 20080714

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090127